BPS804

Phase 2Small molecule

Ultragenyx

BPS804 is one of 63 small molecule programs targeting Hypophosphatasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypophosphatasiaActive, not recruiting

Osteogenesis ImperfectaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

HypophosphatasiaPhase 2

Active, not recruiting

Osteogenesis ImperfectaPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Lorelco

Sanofi

Preclinical

1 4

BPS804

Ultragenyx

Phase 2

1 5

Activase

Flomax

PROCRIT

1 8

Genotropin

EMD Serono

Preclinical

1 9

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Nitrostat

VViatris Specialty LLC

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteogenesis Imperfecta2 trials

Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

Completed· Ultragenyx logo

Ultragenyx·Phase 2·NCT01417091·10 enrolled

An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

Withdrawn· Ultragenyx logo

Ultragenyx·Phase 2·NCT03216486

Low Bone Mineral Density1 trial

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

Completed· Ultragenyx logo

Ultragenyx·Phase 2·NCT01406548·44 enrolled

Chronic Kidney Disease1 trial

Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease

Withdrawn· Ultragenyx logo

Ultragenyx·Phase 2·NCT01806610

Hypophosphatasia1 trial

Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)

Completed· Ultragenyx logo

Ultragenyx·Phase 2·NCT01406977·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for BPS804. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BPS804 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BPS804. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ultragenyx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Ultragenyx

BPS804

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteogenesis Imperfecta2 trials

Low Bone Mineral Density1 trial

Chronic Kidney Disease1 trial

Hypophosphatasia1 trial

References

Drug Info

Quick Facts

Related News